Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder

Thomas J. Spencer, Jeffrey H. Newcorn, Christopher J Kratochvil, Dustin Ruff, David Michelson, Joseph Biederman

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objective. Treatment for attention-deficit/hyperactivity disorder is maintained typically over periods of months or years and, as a result, the potential effects on growth of pharmacotherapy for this disorder have been an area of concern. This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder. Methods. Patients (N = 412) were 6 to 16 years of age at the start of the treatment period and received atomoxetine treatment (maximal dose: 1.8 mg/kg per day) for ≥2 years. Weight and height measurements were analyzed both as actual values and after conversion to percentiles and z scores with growth charts from the Centers for Disease Control and Prevention. Expected weight and height at the end point were calculated through extrapolation from patients' baseline percentiles with the growth charts. Results. Results indicated that, after 2 years, observed weight and height were close to those predicted on the basis of the patients' baseline weight and height. Weight increased an average of 10.8 kg, a decrease relative to baseline normative weight of 2.7 percentiles, corresponding to 0.87 kg. Height increased an average of 13.3 cm, a decrease relative to baseline normative heights of 2.2 percentiles, corresponding to 0.44 cm. For both weight and height, the quartile of patients who were smallest at baseline had an increase in end-point percentile, whereas patients in the highest quartile had a decrease. Conclusions. These findings suggested that, at the group level, there was only a minimal effect on height after 2 years of treatment with atomoxetine and, for patients most at risk (the lowest quartile), there seemed to be no effect.

Original languageEnglish (US)
Pages (from-to)e74-e80
JournalPediatrics
Volume116
Issue number1
DOIs
StatePublished - Dec 1 2005

Fingerprint

Attention Deficit Disorder with Hyperactivity
Pediatrics
Weights and Measures
Growth
Growth Charts
Therapeutics
Growth Disorders
Centers for Disease Control and Prevention (U.S.)
Atomoxetine Hydrochloride
Meta-Analysis
Drug Therapy

Keywords

  • Adolescents
  • Atomoxetine
  • Attention-deficit/hyperactivity disorder
  • Children
  • Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. / Spencer, Thomas J.; Newcorn, Jeffrey H.; Kratochvil, Christopher J; Ruff, Dustin; Michelson, David; Biederman, Joseph.

In: Pediatrics, Vol. 116, No. 1, 01.12.2005, p. e74-e80.

Research output: Contribution to journalArticle

Spencer, Thomas J. ; Newcorn, Jeffrey H. ; Kratochvil, Christopher J ; Ruff, Dustin ; Michelson, David ; Biederman, Joseph. / Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. In: Pediatrics. 2005 ; Vol. 116, No. 1. pp. e74-e80.
@article{a86a7e93a06647579a4bb54fcd0f7236,
title = "Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder",
abstract = "Objective. Treatment for attention-deficit/hyperactivity disorder is maintained typically over periods of months or years and, as a result, the potential effects on growth of pharmacotherapy for this disorder have been an area of concern. This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder. Methods. Patients (N = 412) were 6 to 16 years of age at the start of the treatment period and received atomoxetine treatment (maximal dose: 1.8 mg/kg per day) for ≥2 years. Weight and height measurements were analyzed both as actual values and after conversion to percentiles and z scores with growth charts from the Centers for Disease Control and Prevention. Expected weight and height at the end point were calculated through extrapolation from patients' baseline percentiles with the growth charts. Results. Results indicated that, after 2 years, observed weight and height were close to those predicted on the basis of the patients' baseline weight and height. Weight increased an average of 10.8 kg, a decrease relative to baseline normative weight of 2.7 percentiles, corresponding to 0.87 kg. Height increased an average of 13.3 cm, a decrease relative to baseline normative heights of 2.2 percentiles, corresponding to 0.44 cm. For both weight and height, the quartile of patients who were smallest at baseline had an increase in end-point percentile, whereas patients in the highest quartile had a decrease. Conclusions. These findings suggested that, at the group level, there was only a minimal effect on height after 2 years of treatment with atomoxetine and, for patients most at risk (the lowest quartile), there seemed to be no effect.",
keywords = "Adolescents, Atomoxetine, Attention-deficit/hyperactivity disorder, Children, Growth",
author = "Spencer, {Thomas J.} and Newcorn, {Jeffrey H.} and Kratochvil, {Christopher J} and Dustin Ruff and David Michelson and Joseph Biederman",
year = "2005",
month = "12",
day = "1",
doi = "10.1542/peds.2004-0624",
language = "English (US)",
volume = "116",
pages = "e74--e80",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder

AU - Spencer, Thomas J.

AU - Newcorn, Jeffrey H.

AU - Kratochvil, Christopher J

AU - Ruff, Dustin

AU - Michelson, David

AU - Biederman, Joseph

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Objective. Treatment for attention-deficit/hyperactivity disorder is maintained typically over periods of months or years and, as a result, the potential effects on growth of pharmacotherapy for this disorder have been an area of concern. This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder. Methods. Patients (N = 412) were 6 to 16 years of age at the start of the treatment period and received atomoxetine treatment (maximal dose: 1.8 mg/kg per day) for ≥2 years. Weight and height measurements were analyzed both as actual values and after conversion to percentiles and z scores with growth charts from the Centers for Disease Control and Prevention. Expected weight and height at the end point were calculated through extrapolation from patients' baseline percentiles with the growth charts. Results. Results indicated that, after 2 years, observed weight and height were close to those predicted on the basis of the patients' baseline weight and height. Weight increased an average of 10.8 kg, a decrease relative to baseline normative weight of 2.7 percentiles, corresponding to 0.87 kg. Height increased an average of 13.3 cm, a decrease relative to baseline normative heights of 2.2 percentiles, corresponding to 0.44 cm. For both weight and height, the quartile of patients who were smallest at baseline had an increase in end-point percentile, whereas patients in the highest quartile had a decrease. Conclusions. These findings suggested that, at the group level, there was only a minimal effect on height after 2 years of treatment with atomoxetine and, for patients most at risk (the lowest quartile), there seemed to be no effect.

AB - Objective. Treatment for attention-deficit/hyperactivity disorder is maintained typically over periods of months or years and, as a result, the potential effects on growth of pharmacotherapy for this disorder have been an area of concern. This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder. Methods. Patients (N = 412) were 6 to 16 years of age at the start of the treatment period and received atomoxetine treatment (maximal dose: 1.8 mg/kg per day) for ≥2 years. Weight and height measurements were analyzed both as actual values and after conversion to percentiles and z scores with growth charts from the Centers for Disease Control and Prevention. Expected weight and height at the end point were calculated through extrapolation from patients' baseline percentiles with the growth charts. Results. Results indicated that, after 2 years, observed weight and height were close to those predicted on the basis of the patients' baseline weight and height. Weight increased an average of 10.8 kg, a decrease relative to baseline normative weight of 2.7 percentiles, corresponding to 0.87 kg. Height increased an average of 13.3 cm, a decrease relative to baseline normative heights of 2.2 percentiles, corresponding to 0.44 cm. For both weight and height, the quartile of patients who were smallest at baseline had an increase in end-point percentile, whereas patients in the highest quartile had a decrease. Conclusions. These findings suggested that, at the group level, there was only a minimal effect on height after 2 years of treatment with atomoxetine and, for patients most at risk (the lowest quartile), there seemed to be no effect.

KW - Adolescents

KW - Atomoxetine

KW - Attention-deficit/hyperactivity disorder

KW - Children

KW - Growth

UR - http://www.scopus.com/inward/record.url?scp=33644626937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644626937&partnerID=8YFLogxK

U2 - 10.1542/peds.2004-0624

DO - 10.1542/peds.2004-0624

M3 - Article

C2 - 15995021

AN - SCOPUS:33644626937

VL - 116

SP - e74-e80

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 1

ER -